Medical News Observer

Overview

The syngo.CT Lung CAD device represents a significant advancement in medical imaging technology. It is a Computer-Aided Detection (CAD) tool designed to aid radiologists in identifying solid and subsolid pulmonary nodules. This tool is used during the review of multi-detector computed tomography (MDCT) exams of the chest. Its primary function is to serve as an adjunct tool, highlighting regions of interest (ROI) that could potentially be missed during manual examination. Siemens Healthcare GmbH develops this software. 

Device Description

syngo.CT Lung CAD is a sophisticated algorithm without a dedicated user interface for displaying CAD marks. Instead, it integrates into a hosting application responsible for the user interface component. The software is designed to process thoracic CT examinations, detecting solid pulmonary nodules ranging from 3.0 mm to 30.0 mm and subsolid nodules from 5.0 mm to 30.0 mm in average diameter. It is compatible with multi-detector CT scanners with 16 or more detector rows.

This device is notable for its versatility in detecting a wide range of nodule locations and contours, including central, peripheral, round, and irregular shapes. Once the syngo.CT Lung CAD identifies potential nodule candidates; it sends this information to a visualization application, like Syngo MM Oncology. This results in an output image series with CAD marks superimposed on the input thoracic CT images, facilitating the radiologist’s review process.

Indications

The syngo CT Lung CAD device is indicated for detecting solid and subsolid pulmonary nodules during chest multi-detector computed tomography examinations.

It can be employed in two primary modes. As a concurrent first reader, it is used before the radiologist’s full review. Or a second reader is used after the radiologist’s initial assessment.  Additionally, a “solid-only” mode filters out suspected sub-solid or fully calcified CAD findings. Its role as an adjunctive tool emphasizes its utility in enhancing the radiologist’s ability to spot easily overlooked regions of interest. 

FDA Premarket Authorization

This software received FDA premarket authorization on July 19th, 2023. Substantial equivalence of current iteration(VD30) of the syngo.CT Lung CAD device was tested against its predecessor(VD20). It has been found to maintain the same basic workflow and algorithmic structure based on Convolutional Neural Networks (CNN). The device’s accuracy has been demonstrated to be superior to its predecessor, and it’s considered substantially equivalent in terms of its intended use and technological characteristics.

Conclusion

In summary, the syngo.CT Lung CAD represents a significant tool in modern radiology. It offers a robust, reliable, and efficient means of enhancing the detection of pulmonary nodules. Thereby potentially improving patient outcomes in thoracic imaging.

Reference

• FDA. n.d. “K231157 Syngo.CT Lung CAD Device 510(k) Premarket Notification.” Accessed January 29, 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K231157.